U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07362888) titled 'First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors' on Jan. 15.
Brief Summary: The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.
Study Start Date: Feb. 28
Study Type: INTERVENTIONAL
Condition:
Solid Tumors (Phase 1)
Intervention:
DRUG: ADCE-B05
Biological: Antibody-drug conjugate (ADC)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Adcendo ApS
Published by HT Digital Content Services with permission from Health Daily Digest....